NRD
TVTX icon

Nebula Research & Development’s Travere Therapeutics TVTX Stock Holding History

Nebula Research & Development’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,508
Closed -$161K – 1126
2024
Q3 		$161K Buy
+11,508
New +$120K 0.02% 852
2024
Q2 		– Sell
-12,698
Closed -$97.9K – 1052
2024
Q1 		$97.9K Buy
+12,698
New +$107K 0.02% 691

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nebula Research & Development's TVTX Position: Q4 2024 in Review

Nebula Research & Development sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 11,508 shares — an estimated $161K sold.

Nebula Research & Development first reported a position in TVTX in Q1 2024 and held it in 2 quarters. The position peaked at $161K in Q3 2024. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Nebula Research & Development reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 11,508 Travere Therapeutics shares in Q4 2024, an estimated $161K.
  • Nebula Research & Development first reported a position in Travere Therapeutics in Q1 2024 and held it in 2 quarters.
  • Nebula Research & Development's Travere Therapeutics position peaked at $161K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.